First Case in aap Implantate Study of Silver Coating Technology

By Julie A. Vetalice

First Case in aap Implantate Study of Silver Coating Technology

aap Implantate announced that in 1Q22, first surgeries occurred as part of a human clinical trial to evaluate the company's antibacterial silver coating technology.

aap initiated the human clinical trial in late 2021 as a step toward the planned CE Mark approval of its coating technology.

In addition, aap reports that its antibacterial silver coating technology is effective against the antibiotic-resistant hospital germ methicillin-resistant Staphylococcus aureus (MRSA), which was responsible for 100,000 deaths worldwide in 2019 alone per published studies.

aap's silver coating is intended to offer an alternative solution, not based on antibiotics, in the fight against bacterial infections. As a platform technology, the coating has a broad range of applications and can be used not only in traumatology, but also in other areas of orthopedics.

Source: aap Implantate

Tags: Trial/Study